 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- amelenodor (NX-13) / Landos Biopharma, LABP-73 / Landos Biopharma
THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN (101 - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2637;
Neutrophil and eosinophil infiltration were reduced in UC patients treated with the gut selective NLRX1 agonist, NX-13, and was coupled with better clinical outcomes. The effect of NX-13 on eosinophils will be evaluated further in the ongoing phase 2 NEXUS trial in patients with UC.